GSK3B and hepatocellular carcinoma: CXCL5 has been shown to activate ERK1/2 and PI3K/Akt signaling pathways in HCC cells by interacting with its receptor CXCR212 and activate the ERK/GSK-3β/snail signaling pathway in nasopharyngeal carcinoma cells14.